AbCellera Biologics (NASDAQ:ABCL) Trading 8.7% Higher After Analyst Upgrade

AbCellera Biologics Inc. (NASDAQ:ABCL)’s stock price traded up 8.7% during mid-day trading on Tuesday after Truist Financial raised their price target on the stock from $12.00 to $30.00. Truist Financial currently has a buy rating on the stock. AbCellera Biologics traded as high as $9.96 and last traded at $10.1520. 4,091,649 shares traded hands during mid-day trading, a decline of 32% from the average daily volume of 5,976,931 shares. The stock had previously closed at $9.34.

Other equities research analysts also recently issued research reports about the company. Stifel Nicolaus raised their price objective on AbCellera Biologics from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Wall Street Zen lowered shares of AbCellera Biologics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Cantor Fitzgerald raised their price target on shares of AbCellera Biologics from $11.00 to $12.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AbCellera Biologics in a research report on Friday, July 17th. Finally, Benchmark upgraded shares of AbCellera Biologics from a “hold” rating to a “buy” rating and set a $11.00 price objective for the company in a research note on Tuesday, July 7th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, AbCellera Biologics has a consensus rating of “Moderate Buy” and an average target price of $12.83.

Trending Headlines about AbCellera Biologics

Here are the key news stories impacting AbCellera Biologics this week:

• Positive Sentiment: Strong Phase 2 results provide a major catalyst. ABCL635 delivered positive data in menopausal vasomotor symptoms, improving confidence that the program could advance toward later-stage development and potentially become a commercial product. Analysts and market commentators described the result as AbCellera’s first meaningful pipeline win. AbCellera Biologics Is Up 60.3% After Strong Phase 2 Menopause Data AbCellera Gets Its First Pipeline Win With Positive Phase 2 Data
• Positive Sentiment: Analyst optimism increased. Truist raised its price target from $12 to $30 and maintained a Buy rating, indicating that the clinical data materially changed its valuation outlook. Truist Raises AbCellera Price Target
• Positive Sentiment: Unusually heavy call-option activity signals bullish positioning. Investors purchased substantially more ABCL call options than usual, suggesting traders were positioning for continued volatility or further gains. Options activity, however, does not guarantee sustained demand for the shares. Investors Buy Large Volume of AbCellera Call Options
• Neutral Sentiment: Some commentary views the menopause program favorably but questions whether the results validate AbCellera’s broader antibody-discovery platform, leaving the company’s longer-term growth narrative unsettled. AbCellera: Excellent Phase 2 Data in Menopause but the Platform Narrative Is Fading
• Negative Sentiment: AbCellera proposed a $200 million public offering of shares and pre-funded warrants. The financing strengthens the balance sheet and could fund development, but the new securities may dilute existing shareholders and weigh on the stock after its rally. AbCellera Announces Proposed Public Offering
• Negative Sentiment: One valuation analysis argues the shares could be roughly 33% overvalued following the Phase 2 reaction, highlighting execution, commercialization, and valuation risks. AbCellera Could Be 33% Overvalued Following Phase 2 Results

Institutional Investors Weigh In On AbCellera Biologics

Large investors have recently modified their holdings of the business. AssuredPartners Investment Advisors LLC acquired a new stake in AbCellera Biologics in the 4th quarter worth approximately $34,000. Voleon Capital Management LP purchased a new position in shares of AbCellera Biologics in the third quarter worth $56,000. Engineers Gate Manager LP acquired a new stake in shares of AbCellera Biologics during the fourth quarter worth $38,000. Allworth Financial LP lifted its stake in shares of AbCellera Biologics by 857.0% during the fourth quarter. Allworth Financial LP now owns 11,274 shares of the company’s stock worth $39,000 after buying an additional 10,096 shares during the period. Finally, Janney Montgomery Scott LLC purchased a new stake in shares of AbCellera Biologics during the first quarter valued at $46,000. Hedge funds and other institutional investors own 61.42% of the company’s stock.

AbCellera Biologics Price Performance

The business’s fifty day moving average price is $6.45 and its two-hundred day moving average price is $4.81. The stock has a market capitalization of $3.17 billion, a PE ratio of -19.17 and a beta of 1.20.

AbCellera Biologics (NASDAQ:ABCL) last issued its earnings results on Wednesday, August 5th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.02). The firm had revenue of $4.05 million during the quarter, compared to analysts’ expectations of $7.85 million. AbCellera Biologics had a negative return on equity of 17.49% and a negative net margin of 248.83%. As a group, equities research analysts anticipate that AbCellera Biologics Inc. will post -0.68 earnings per share for the current fiscal year.

About AbCellera Biologics

AbCellera Biologics Inc (NASDAQ: ABCL) is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection.

AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis.